image
Healthcare - Drug Manufacturers - Specialty & Generic - NASDAQ - US
$ 6.48
0.621 %
$ 240 M
Market Cap
-11.57
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jan, 18, 2025.

The intrinsic value of one LFCR stock under the worst case scenario is HIDDEN Compared to the current market price of 6.48 USD, Lifecore Biomedical, Inc. is HIDDEN

This DCF valuation model was last updated on Jan, 18, 2025.

The intrinsic value of one LFCR stock under the base case scenario is HIDDEN Compared to the current market price of 6.48 USD, Lifecore Biomedical, Inc. is HIDDEN

This DCF valuation model was last updated on Jan, 18, 2025.

The intrinsic value of one LFCR stock under the best case scenario is HIDDEN Compared to the current market price of 6.48 USD, Lifecore Biomedical, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS
FINANCIALS
128 M REVENUE
24.20%
9.33 M OPERATING INCOME
135.77%
9.33 M NET INCOME
109.13%
-217 K OPERATING CASH FLOW
99.37%
-17.9 M INVESTING CASH FLOW
-331.52%
7.51 M FINANCING CASH FLOW
-81.09%
32.6 M REVENUE
31.81%
-1.96 M OPERATING INCOME
83.09%
-6.57 M NET INCOME
59.51%
-6.11 M OPERATING CASH FLOW
-850.23%
-2.47 M INVESTING CASH FLOW
27.18%
12.5 M FINANCING CASH FLOW
1045.01%
Balance Sheet Lifecore Biomedical, Inc.
image
Current Assets 81 M
Cash & Short-Term Investments 8.46 M
Receivables 31.2 M
Other Current Assets 41.4 M
Non-Current Assets 173 M
Long-Term Investments 0
PP&E 151 M
Other Non-Current Assets 21.9 M
Current Liabilities 38.9 M
Accounts Payable 16.3 M
Short-Term Debt 4.91 M
Other Current Liabilities 17.6 M
Non-Current Liabilities 181 M
Long-Term Debt 125 M
Other Non-Current Liabilities 55.5 M
EFFICIENCY
Earnings Waterfall Lifecore Biomedical, Inc.
image
Revenue 128 M
Cost Of Revenue 86.4 M
Gross Profit 41.8 M
Operating Expenses 49 M
Operating Income 9.33 M
Other Expenses 0
Net Income 9.33 M
RATIOS
32.63% GROSS MARGIN
32.63%
7.28% OPERATING MARGIN
7.28%
9.37% NET MARGIN
9.37%
22.29% ROE
22.29%
4.39% ROA
4.39%
5.22% ROIC
5.22%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Lifecore Biomedical, Inc.
image
Net Income 9.33 M
Depreciation & Amortization 8.86 M
Capital Expenditures -17.9 M
Stock-Based Compensation 6.2 M
Change in Working Capital -3.84 M
Others -16.6 M
Free Cash Flow -18.1 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Lifecore Biomedical, Inc.
image
Wall Street analysts predict an average 1-year price target for LFCR of $6.5 , with forecasts ranging from a low of $5 to a high of $8 .
LFCR Lowest Price Target Wall Street Target
5 USD -22.84%
LFCR Average Price Target Wall Street Target
6.5 USD 0.31%
LFCR Highest Price Target Wall Street Target
8 USD 23.46%
4. DIVIDEND ANALYSIS
5. COMPETITION
6. Ownership
Insider Ownership Lifecore Biomedical, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
7.2 M USD 2
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
3 months ago
Oct 03, 2024
Bought 696 K USD
WYNNEFIELD PARTNERS SMALL CAP VALUE LP I
10 percent owner
+ 169753
4.1 USD
3 months ago
Oct 03, 2024
Bought 504 K USD
WYNNEFIELD PARTNERS SMALL CAP VALUE LP I
10 percent owner
+ 122930
4.1 USD
3 months ago
Oct 03, 2024
Bought 5.38 M USD
Kiper Christopher S
director, 10 percent owner:
+ 1311312
4.1 USD
3 months ago
Oct 03, 2024
Bought 624 K USD
Kiper Christopher S
director, 10 percent owner:
+ 152102
4.1 USD
2 years ago
Nov 25, 2022
Bought 2.25 M USD
WYNNEFIELD PARTNERS SMALL CAP VALUE LP I
Director
+ 282486
7.97 USD
2 years ago
Nov 25, 2022
Bought 2.75 M USD
WYNNEFIELD PARTNERS SMALL CAP VALUE LP I
Director
+ 345260
7.97 USD
2 years ago
Jan 09, 2023
Bought 1.56 M USD
WYNNEFIELD PARTNERS SMALL CAP VALUE LP I
Director
+ 1560
1000 USD
2 years ago
Jan 09, 2023
Bought 1.04 M USD
WYNNEFIELD PARTNERS SMALL CAP VALUE LP I
Director
+ 1040
1000 USD
2 years ago
Jan 09, 2023
Bought 650 K USD
WYNNEFIELD PARTNERS SMALL CAP VALUE LP I
Director
+ 650
1000 USD
2 years ago
Jan 09, 2023
Bought 10.9 K USD
WYNNEFIELD PARTNERS SMALL CAP VALUE LP I
10 percent owner
+ 1560
7 USD
2 years ago
Jan 09, 2023
Bought 7.28 K USD
WYNNEFIELD PARTNERS SMALL CAP VALUE LP I
10 percent owner
+ 1040
7 USD
2 years ago
Jan 09, 2023
Bought 4.55 K USD
WYNNEFIELD PARTNERS SMALL CAP VALUE LP I
10 percent owner
+ 650
7 USD
7. News
Bronstein, Gewirtz & Grossman, LLC Encourages Lifecore Biomedical, Inc. (LFCR) Stockholders to Inquire about Securities Investigation NEW YORK CITY, NY / ACCESSWIRE / January 7, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR). Investors who purchased Lifecore securities prior to October 7, 2020, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/LFCR. accesswire.com - 1 week ago
Lifecore Biomedical Further Strengthens Financial Position Through Sale of Excess Capital Equipment for $17 Million Company Believes it is Well Positioned for Mid-Term and Long-Term Growth as Current Capacity Continues to Support up to $300 Million in Annual Revenue globenewswire.com - 1 week ago
Lifecore Biomedical to Participate at 43rd Annual J.P. Morgan Healthcare Conference CHASKA, Minn., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company will participate at the 43rd Annual J.P. Morgan Healthcare Conference. The conference will take place January 13-16, 2025, in San Francisco, California. globenewswire.com - 1 week ago
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Lifecore Biomedical, Inc. (LFCR) and Encourages Investors to Learn More About the Investigation NEW YORK, NY / ACCESSWIRE / January 6, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR). Investors who purchased Lifecore securities prior to October 7, 2020, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/LFCR. accesswire.com - 1 week ago
LFCR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces an Investigation into Lifecore Biomedical, Inc. and Encourages Investors to Contact the Firm NEW YORK CITY, NY / ACCESSWIRE / January 5, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR). Investors who purchased Lifecore securities prior to October 7, 2020, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/LFCR. accesswire.com - 2 weeks ago
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Lifecore Biomedical, Inc. (LFCR) And Encourages Stockholders to Reach Out NEW YORK CITY, NY / ACCESSWIRE / January 3, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR). Investors who purchased Lifecore securities prior to October 7, 2020, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/LFCR. accesswire.com - 2 weeks ago
Lifecore Biomedical (LFCR) Reports Q2 Loss, Tops Revenue Estimates Lifecore Biomedical (LFCR) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.06 per share a year ago. zacks.com - 2 weeks ago
Lifecore Biomedical, Inc. (LFCR) Q2 2025 Earnings Call Transcript Lifecore Biomedical, Inc. (NASDAQ:LFCR ) Q2 2025 Earnings Conference Call January 2, 2025 4:00 PM ET Company Participants Stephanie Diaz - Manager, IR Paul Josephs - President & CEO Ryan Lake - CFO Conference Call Participants Matt Hewitt - Craig-Hallum Capital Group Jacob Johnson - Stephens Michael Petusky - Barrington Research Operator Good afternoon, and thank you for joining Lifecore's Financial 2025 Second Quarter Earnings Call. During the call, all participants will be in a listen-only mode. seekingalpha.com - 2 weeks ago
Lifecore Biomedical Reports Second Quarter Fiscal 2025 Financial Results and Provides Corporate Update -- Recorded Revenues of $32.6 Million for Q2 Fiscal 2025 -- -- Signed Multiple Development Agreements with New Customers -- globenewswire.com - 2 weeks ago
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Lifecore Biomedical, Inc. (LFCR) and Encourages Stockholders to Learn More About the Investigation NEW YORK CITY, NY / ACCESSWIRE / December 31, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR). Investors who purchased Lifecore securities prior to October 7, 2020, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/LFCR. accesswire.com - 2 weeks ago
Bronstein, Gewirtz & Grossman, LLC Encourages Lifecore Biomedical, Inc. (LFCR) Investors to Inquire about Securities Investigation NEW YORK CITY, NY / ACCESSWIRE / December 30, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR). Investors who purchased Lifecore securities prior to October 7, 2020, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/LFCR. accesswire.com - 2 weeks ago
Bronstein, Gewirtz & Grossman, LLC Encourages Lifecore Biomedical, Inc. (LFCR) Stockholders to Inquire about Securities Investigation NEW YORK, NY / ACCESSWIRE / December 29, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ:LFCR). Investors who purchased Lifecore securities prior to October 7, 2020, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/LFCR. accesswire.com - 3 weeks ago
8. Profile Summary

Lifecore Biomedical, Inc. LFCR

image
COUNTRY US
INDUSTRY Drug Manufacturers - Specialty & Generic
MARKET CAP $ 240 M
Dividend Yield 0.00%
Description Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. It operates through Lifecore, Curation Foods, and Other segments. The Lifecore segment engages in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, including technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. This segment sells its non-HA products for medical use primarily in the ophthalmic, orthopedic, and other markets. The Curation Foods segment engages in processing, marketing, and selling of olive oils and wine vinegars under the O brand; and guacamole and avocado food products under the Yucatan and Cabo Fresh brands, as well as various private labels. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was incorporated in 1986 and is headquartered in Santa Maria, California.
Contact 3515 Lyman Boulevard, Chaska, MN, 55318 https://www.lifecore.com
IPO Date Feb. 15, 1996
Employees 524
Officers Mr. Paul Josephs President, Chief Executive Officer & Director Ms. Jackie Q. Klecker Executive Vice President, Quality and Development Services & GM Mr. Matt Augustson Senior Vice President of Information Technology Mr. Parker K. Javid Vice President Mr. James G. Hall Advisor Mr. Aaron Perlitsh Director of Internal Audit & Chief Compliance Officer Mr. Darren M. Hieber Senior Vice President of Corporate Development & Partnerships Ms. Brikkelle Thompson Senior Vice President of Human Resources Mr. Ryan D. Lake CPA Chief Financial Officer & Secretary Dr. Albert D. Bolles Ph.D. President of Curation Foods, Inc.